Insmed Incorporated (INSM) PT Lifted to $230 as Guggenheim Updates Biotech Earnings Models
TheFly reported on April 16 that Guggenheim Securities increased its price target on INSM from $227 to $230 while maintaining a Buy rating.
Insmed Inc (INSM)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bayforest Capital Theodoros Tsagaris | 326 | $53,308 | -78% | 0.06% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $66.35 | 1,130 | $74,975.50 | 3,025 | 2025-05-21 | Filing | |
| $66.87 | 1,895 | $126,718.65 | 1,895 | 2025-05-20 | Filing | |
| $19.29 | 10,000 | $192,900.00 | 10,000 | 2023-05-15 | Filing | |
| $19.29 | 10,000 | $192,900.00 | 298,615 | 2023-05-15 | Filing | |
| $17.70 | 10,000 | $177,000.00 | 15,900 | 2022-11-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $145.79 | 825 | $120,276.75 | 301,185 | 2026-04-16 | Filing | |
| $144.66 | 2,255 | $326,208.30 | 302,010 | 2026-04-16 | Filing | |
| $143.81 | 5,373 | $772,691.13 | 304,265 | 2026-04-16 | Filing | |
| $142.99 | 2,246 | $321,155.54 | 309,638 | 2026-04-16 | Filing | |
| $164.01 | 1,434 | $235,190.34 | 301,185 | 2026-04-06 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,102,248 | $178,658,787 | 0.19% | |
| 2. | 365,000 | $59,684,800 | 0.67% | |
| 3. | 283,141 | $46,299,216 | 0.07% | |
| 4. | 142,580 | $23,314,682 | 0.36% | |
| 5. | 114,788 | $18,770,141 | 0.06% |
News See All
Top 10 AI-Powered Biotech Stocks to Buy Right Now
Franklin Equity reported on February 16 that, following a protracted period of uncertainty in the previous year, the biotechnology sector has entered 2026 on a firmer and more stable foundation.
9 Best QQQ Stocks to Buy Now
On April 8, Yung-Yu Ma of PNC joined 'Fast Money' on CNBC to discuss the current market environment and noted that worst-case scenarios are not yet priced into the VIX or oil futures curves.
Billionaire Stan Druckenmiller's 10 Small and Mid-Cap Stock Picks with Huge Upside Potential
Stanley Druckenmiller, the chief of New York-based investment firm Duquesne Capital, oversees a 13F portfolio at his hedge fund that was worth close to $4.5 billion at the end of the fourth quarter of...
Stifel Lifts PT on Insmed Incorporated (INSM) to $208 From $205 - Here's Why
Insmed Incorporated (NASDAQ:INSM) is one of the best high growth healthcare stocks to buy now. Stifel raised the price target on Insmed Incorporated (NASDAQ:INSM) to $208 from $205 on March 24, reaffirming...
Insmed (INSM) Jumps as Morgan Stanley Raises PT by 28%
Insmed snapped a two-day losing streak on Monday, adding 5.52 percent to close at $153.32 apiece, as investors took path from Morgan Stanley’s rating and 28-percent price target upgrade for its stock...
10 Stocks Leaving the Market in the Dust Today: Insmed, FMC, Alcoa, and More
Ten stocks stood firmer on Monday, clocking gains and bucking a mostly pessimistic broader market, as investors gobbled up shares ahead of dividend payments, while digesting analyst ratings and other ...
11 High Growth Healthcare Stocks to Buy Now
On March 26, Stephanie Link, Hightower chief investment strategist, appeared on CNBC's ‘Squawk Box’ to talk about the latest market trends, where investors can find opportunities, and the effects ...
Artisan Small Cap Fund Sold Insmed (INSM) on Valuation Consideration
Artisan Partners, an investment management company, released its fourth-quarter 2025 investor letter for “Artisan Small Cap Fund”. A copy of the letter can be downloaded here.
Insmed Incorporated (INSM) Price Target Raised to $211 at BofA
On February 20, BofA analyst Jason Zemansky raised the firm’s price target on Insmed Incorporated (NASDAQ:INSM) to $211 from $209 and maintained a Buy rating.
Hedge Fund Resource Center